Compare Global X FTSE Southeast Asia ETF (ASEA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Novavax Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.47, while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | NVAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $21.53 | $11.19 |
52-Week Low | $16.86 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
